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Introduction:  
Meningiomas are the most common primary tumours of the central nervous system 
in adults and despite the majority of them displaying benign features they can cause 
mild to severe morbidity. The current main therapeutic approach is complete 
resection commonly with adjunct radiotherapy. No pharmaceutical treatment is 
available and surgical resection is not always possible, so new therapeutic options 
are needed. 
In the context of molecular targeted therapy, we aim to identify novel 
targets/biomarkers by deciphering both the proteome and phosphoproteome in 
stratified meningiomas. 
Material and Methods:  
Meningiomas were stratified based on their histological grade defined by the World 
Health Organization (WHO). A total of 5 grade I, 5 grade II and 4 grade III 




Equal amounts of total proteins were loaded on a gradient SDS-PAGE and evenly 
separated bands were fractionated and tryptic digested. Extracted peptides were 
purified and analysed by liquid chromatography–tandem mass spectrometry (LC-
MS/MS). Phosphoprotein purification was performed using Qiagen® PhosphoProtein 
Purification Kit. Phosphoproteins were processed as before. Raw mass spectrometry 
files were analysed using MaxQuantTM and data were processed by using DAVID 6.7 
and the Ingenuity® Pathway Analysis (IPA) software. 
Results:  
We have identified approximately 3000 proteins across the 14 samples with over 
2000 quantified; similar numbers were obtained for phosphoproteins. Over 600 
candidates were commonly identified across the grades for the total proteome, and 
over 800 for the phosphoproteome, which were not quantified in normal meningeal 
tissue. Additional proteins and phosphoproteins were found to be grade-specific. 
Gene ontology (GO) enrichment analysis of upregulated proteins (fold change 1.5; p-
value <0.05) revealed several up-regulated biological processes. After uploading the 
datasets to IPA, comparative analysis of primary meningiomas vs. normal meningeal 
tissue showed several dysregulated pathways. Among the most affected pathways 
identified were the mTOR, integrin and ERK/MAPK signalling. Notably, using this 
tool we identified several novel targets associated with an already available drug, 
either in clinical practice or trial. These targets will be validated first as well as the 
efficacy of specific repositioned drugs in an effort of making this study time and cost 
effective. 
Conclusions:  
Proteome and phosphoproteome analysis of different grade meningiomas revealed 
several potential novel targets/biomarkers and dysregulated pathways, 
demonstrating the effectiveness of the proteomic approach. Our studies increased 
the overall knowledge of protein expression and regulation in meningiomas and will 
give the rationale for future drug testing on common or stratified targets. 
